In the TRIUMPH-1 Phase 3 trial, participants on the highest dose of retatrutide lost an average of 28.3% of their body weight at 80 weeks
This analysis is based on Planet Fitness Q4 2025 earnings releases and call transcripts, Life Time Group Holdings 8-K filings and earnings call transcripts, the Ro press release announcing the Serena Williams partnership, Athletech News, CNBC, Bloomberg, NBC News, the New England Journal of Medicine, Morgan Stanley Research notes on GLP-1 consumer impact, and reporting from Quartz, Fast Company, and the Boring Business Nerd newsletter
Instead of aiming immediately toward standard therapeutic dose levels, microdosing focuses on smaller medication exposure, slower escalation, and a gentler patient experience
MTC is very rare, accounting for only about 1% to 3% of all thyroid cancer cases in the UK